Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.

Trial Details

NCT ID
NCT06609876
Phase
NA
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Thermal ablation
  • Donafenib
Locations (sample)
  • Beijing, None Selected, China|39.9075,116.39723

Key Eligibility Criteria

  • were aged 18-75 years;
  • had recurrent HCC (RHCC) diagnosed by imaging studies, the first or the second RHCC;
  • RHCC met the Milan criteria, namely single RHCC lesion less than 5 cm in diameter or no more than 3 tumors (each ≤3 cm in diameter);
  • the early RHCC (recurrent time \<1 year)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →